The FDA has approved an IND for a Phase 2 study of GeneOne Life Science’s GLS-1200 nasal spray for the prevention of COVID-19, the company said. According to GeneOne, GLS-1200 stimulates nasal production of nitric oxide, which has been shown to inhibit coronavirus activity.
The study of GLS-1200 for prevention of COVID-19 is expected to enroll 225 healthcare workers who are at high risk for SARS-CoV-2 infection. Subjects will be randomized to self-administer either GLS-1200 nasal spray or placebo three times per day over four weeks.
GeneOne Chief Medical Officer Joel N. Maslow said, “having a prophylactic treatment like GLS-1200 that is easily scalable and nasally administered to the point of entry of the virus can provide significant benefit.”
CEO Young K. Park commented, “We have moved quickly to enable GeneOne to supply millions of doses, as we anticipate the Phase 2 study of GLS-1200 will demonstrate effectiveness in preventing infection.”
GLS-1200 is also in Phase 2 development for the prevention of sinusitis following endoscopic sinus surgery.
Read the GeneOne Life Science press release.
